Clinical Trials at Youssef Hanna, MD
During the past decade, Youssef Hanna, MD conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 0 clinical trials were completed, i.e. on
average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0%
of trials that started reached the finish line.
Clinical Trials Sponsors and Collaborators
Clinical Trials Conditions at Youssef Hanna, MD
According to Clinical.Site data, the most researched conditions in "Youssef Hanna, MD" are
"Carcinoma, Non-Small Cell Lung" (1 trials), "Carcinoma, Non-Small-Cell Lung" (1 trials), "Lung Cancer" (1 trials), "Neoplasms, Lung" (1 trials) and "Neoplasms, Pulmonary" (1 trials). Many other conditions were trialed in "Youssef Hanna, MD" in a lesser frequency.
Clinical Trials Intervention Types at Youssef Hanna, MD
Most popular intervention types in "Youssef Hanna, MD" are "Drug" (2 trials). Other intervention types were less common.
The name of intervention was led by "docetaxel" (1 trials), "pemetrexed" (1 trials), "talabostat" (1 trials) and "talabostat mesylate" (1 trials). Other intervention names were less common.
Clinical Trials Genders at Youssef Hanna, MD
The vast majority of trials in "Youssef Hanna, MD" are
2 trials for "All" genders.
Clinical Trials Status at Youssef Hanna, MD
Currently, there are NaN active trials in "Youssef Hanna, MD".
undefined are not yet recruiting,
undefined are recruiting,
undefined are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were undefined completed trials in Youssef Hanna, MD,
undefined suspended trials,
and 2 terminated clinical trials to date.
Out of the total trials that were conducted in Youssef Hanna, MD, 0 "Phase 1"
clinical trials were conducted, 0 "Phase 2" clinical
trials and 2 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 0 trials that are defined as “Not Applicable".